KMID : 1143420210140221500
|
|
Public Health Weekly Report 2021 Volume.14 No. 22 p.1500 ~ p.1509
|
|
Analysis of transmission period among patients with 501Y.V1 in Republic of Korea
|
|
Kim Ji-A
Park Su-Bin Kim Jung-Yeon Gwack Jin Kim Jeong-Min Jo Hye-Jun Lee Nam-Joo Kim Heui-Man Rhee Jee-Eun Kim Eun-Jin
|
|
Abstract
|
|
|
After being confirmed as 501Y.V1 on September 20, 2020, about 125 countries have confirmed the 501Y.V1, and the recent COVID-19 pandemic in Brazil has become serious due to the 501Y.V3[1]. A total of 330 Variant of Concern (VOCs) were confirmed by April 5, after the first case was confirmed in Republic of Korea in December 2020. Since January 2, 2021, the Central Disease Control Headquarters has been managing VOCs and suspects by applying "the enhanced case management guidelines" to prevent the inflow and spread of variant in Korea. Therefore, we decided to derive an appropriate isolation period based on scientific grounds for analysis, which accounts for guidance on discharging patients with 501Y.V1 in Korea. Except for factors such as severe/critical, death, etc. that may affect the transmission period; 501Y.V1 group was selected for 78 and Non-501Y.V1 group for 311 (May, 2020). Further analysis was conducted on 522 501Y.V1 and 522 Non-501Y.V1 group (May, 2020) including 211 unconfirmed Ct values in Polymerase Chain Reaction (PCR) tests during isolation, 851 Non501Y.V1 group (April, 2020) to comprised the difference between the period of PCR negative conversion. The distribution of Ct values in PCR tests was similar during isolation between the 501Y.V1 group and the Non-501Y.V1 group (May, 2020), and within five days of symptoms or confirmed date, 10 samples with Ct value (RdRp) below 24.68 were negative, and the remaining 30 samples were negative. In addition, the median was 30 days for 501Y.V1 group, 33 days for non-501Y.V1 group (April, 2020) and 26 days for non-501Y. V1 group (May, 2020) with differences in the distribution of infection routes. The difference in period of PCR negative conversion is expected to take into account the impact of patient characteristics (such as underlying disease and age) according to infection routes rather than infection with COVID-19 variant. The analysis is meaningful in that it has been able to lay the groundwork for clinical-based guidance on discharging patients as a way to manage patients with the 501Y.V1 by confirming that transmission period of the 501Y.V1 is no different from the COVID-19. In the future, it is necessary to establish a scientific evidence-based strategy to respond to VOCs by continuously analyzing the epidemiological and clinical information of patients with 501Y.V2., 501Y.V3. as well as from the 501Y.V1.
|
|
KEYWORD
|
|
Covid-19, Variant of Concern (VOC), 501Y.V1, Transmission period
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|